Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of HS-10380 in Chinese Adult Patients With Schizophrenia
NCT07759869Phase 3Not yet recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Sep 2026
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
A Phase 3 trial of obuprazine in schizophrenia, sponsored by Hansoh Pharmaceutical Group. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
obuprazine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT07759869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07759869.